We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Epogen Reimbursement Problems May Signal Part D Troubles
Epogen Reimbursement Problems May Signal Part D Troubles
September 15, 2006
Flaws in the Centers for Medicare & Medicaid Services’ (CMS) reimbursement policy for Amgen’s anemia drug Epogen may foretell problems with the Part D drug plan, researchers say.